Ignite Creation Date:
2024-05-06 @ 2:52 AM
Last Modification Date:
2024-10-26 @ 11:24 AM
Study NCT ID:
NCT02147015
Status:
COMPLETED
Last Update Posted:
2020-10-26
First Post:
2014-05-22
Brief Title:
Personalized Variable Versus Fixed Dose Glucocorticoid Therapy in AECOPD
Sponsor:
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Organization:
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Study Overview
Official Title:
Personalized Variable Versus Fixed Dose Corticosteroids Therapy in Hospitalized Patients With Acute Exacerbations of Chronic Obstructive Pulmonary Disease
Status:
COMPLETED
Status Verified Date:
2020-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The hypothesis is that in acute exacerbated Chronic Obstructive Pulmonary Disease AECOPD personalized variable dose glucocorticoid treatment will result in superior clinical outcome when compared to fixed dose therapy
Detailed Description:
Treatment with glucocorticoid for acute exacerbations of COPD results in the improvement of clinical outcomes However the optimal doses of glucocorticoid for each individual patient has not been determined According to GOLD Report 2014 a dose of 40 mg prednisone per day for 5 days is recommended Evidence B although there are insufficient data to provide firm conclusions concerning the optimal duration of corticosteroid therapy of acute exacerbations of COPD The purpose of the current study is to compare clinical outcomes of personalized or fixed dose of glucocorticoid in patients with acute exacerbations of COPD
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None